Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Share-based Compensation (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Share-based Compensation for 8 consecutive years, with $6.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 24.11% year-over-year to $6.8 million, compared with a TTM value of $25.4 million through Dec 2025, down 33.12%, and an annual FY2025 reading of $25.4 million, down 33.12% over the prior year.
  • Share-based Compensation was $6.8 million for Q4 2025 at Arcturus Therapeutics Holdings, up from $5.7 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $10.1 million in Q1 2024 and bottomed at $5.7 million in Q3 2025.
  • Average Share-based Compensation over 5 years is $7.9 million, with a median of $7.5 million recorded in 2021.
  • The sharpest move saw Share-based Compensation soared 722.97% in 2021, then tumbled 39.65% in 2025.
  • Year by year, Share-based Compensation stood at $7.5 million in 2021, then fell by 13.14% to $6.5 million in 2022, then surged by 34.99% to $8.8 million in 2023, then rose by 1.91% to $9.0 million in 2024, then dropped by 24.11% to $6.8 million in 2025.
  • Business Quant data shows Share-based Compensation for ARCT at $6.8 million in Q4 2025, $5.7 million in Q3 2025, and $6.2 million in Q2 2025.